Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades Ashland to Underweight, Raises Price Target to $105

JP Morgan analyst Jeffrey Zekauskas downgrades Ashland (NYSE:ASH) from Neutral to Underweight and raises the price target from $104 to $105.
byBenzinga Newsdesk
February 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Jeffrey Zekauskas downgrades Ashland (NYSE:ASH) from Neutral to Underweight and raises the price target from $104 to $105.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Compass Therapeutics Receives FDA Fast Track Designation For The Investigation Of CTX-009 In Combination With Paclitaxel For The Treatment Of Patients With Metastatic Or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

By Benzinga Newsdesk
April 25, 8:01 AM
CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 studyTop-line data

CMPX